Skip to main content
x
Dartmouth-Hitchcock logo
Summer Flowers In This Section

An International, Double-blind, Randomized, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)

Principal Investigator

Lauren Gilstrap

Study Number

F19029

Summary

To determine whether dapagliflozin (Farxiga)is superior to placebo, when added to standard of care, in reducing the composite of cardiovascular death or hospitalization. Farxiga is a drug for the treatment of diabetes and has been found to improve the quality of life for heart failure patients by promoting the reduction of glucose.

Phase

N/A

Contact

Brian Aldrich

Available at the following location(s)

  • Lebanon

View more details at ClinicalTrials.gov

Do you need help with some of the labels on this page?
Read our glossary of terms

0